A phase I first-in-human trial to investigate safety, tolerability and pharmacokinetics of PTI-125 in healthy human volunteers

Trial Profile

A phase I first-in-human trial to investigate safety, tolerability and pharmacokinetics of PTI-125 in healthy human volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Dec 2017

At a glance

  • Drugs PTI-125 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Most Recent Events

    • 14 Dec 2017 According to a Pain Therapeutics media release, full results of this study were presented at the 10th Annual International Conference on Clinical Trials on Alzheimers Disease (CTAD) 2017.
    • 24 Oct 2017 According to a Pain Therapeutics media release, this trial was supported with research grant award from the National Institute on Aging, part of the National Institutes of Health.
    • 24 Oct 2017 According to a Pain Therapeutics media release, full results of this study will be presented at the 10th Annual International Conference on Clinical Trials on Alzheimers Disease (CTAD) 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top